For research use only. Not for therapeutic Use.
F 16915, a Docosahexaenoic Acid (DHA, HY-B2167) derivative, is a potent pro-agent of DHA. F 16915 can prevent heart failure-induced atrial fibrillation[1].
F 16915 (100 mg/kg; daily oral gavage for 2 months) reduces marked dilation of the left atrial (LA) cavity and the steep decline of left ventricular (LV) contractile function occurring 2 months after infarction and reperfusion in rats[1].
F 16915 (1-5 g/day for 4 weeks) significantly reduces the infarct size and prevents the left ventricular free wall thinning[1].
| Catalog Number | I020418 |
| CAS Number | 92510-91-3 |
| Synonyms | pyridin-3-ylmethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate |
| Molecular Formula | C28H37NO2 |
| Purity | ≥95% |
| InChI | InChI=1S/C28H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-23-28(30)31-26-27-22-21-24-29-25-27/h3-4,6-7,9-10,12-13,15-16,18-19,21-22,24-25H,2,5,8,11,14,17,20,23,26H2,1H3/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18- |
| InChIKey | BUWVEXMRBAWBPJ-KUBAVDMBSA-N |
| SMILES | CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCC1=CN=CC=C1 |
| Reference | [1]. Le Grand B, et al. F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):667-77. |
